The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

The Rio-based network of independent pharmacies blames drug industry intermediaries known as pharmacy benefit managers.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

The pharmacy benefit managers, which were named in two of the complaints—CVS Caremark, Express Scripts, MedImpact, and ...

CVS did not break out separate enrollment figures for fully insured group health plans when it posted its earnings.

TD Cowen analyst Charles Rhyee maintained a Buy rating on CVS Health (CVS – Research Report) today and set a price target of $85.00. The ...

Cantor Fitzgerald analyst Sarah James maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of ...

Steve Nelson, a former chief executive officer of UnitedHealthcare, has been named the president of Hartford-based Aetna, ...

CVS Health today announced Prem Shah will be group president, and will continue to report to David Joyner, president and CEO. In addition, the company announced the appointment of Steve Nelson as ...

CVS Health fell short on third-quarter profit, but it posted strong sales and the health care giant shook up leadership under ...

But today, according to the Federal Trade Commission, the six largest PBMs — CVS Caremark, Express Scripts, OptumRx, Humana, Prime Therapeutics and MedImpact — manage nearly 95% of all prescriptions ...

Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...